Tag: Atai Life Sciences

Avatar photoAdam JacksonNovember 10, 2022
atai-1280x720.jpg

4min00
Clinical-stage biopharmaceutical company atai Life Sciences (Nasdaq: ATAI) reported financial results for the third quarter ending Sept. 30, providing updates on its clinical trials looking at the treatment of depression using ketamine – particularly an at-home therapy for treatment-resistant depression. “In addition to multiple study initiations this quarter, we have announced two positive clinical trial […]

Avatar photoStaffAugust 15, 2022
daily_hit001-1280x367.png

13min00
The Daily Hit is a recap of cannabis business news for August 15, 2022. ON THE SITE Auxly Revenues Improve, Tries to Cut Costs Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF)  released its financial results for the three months ending June 30, 2022. Total net revenues from the sale of adult-use cannabis in Canada […]

Avatar photoDave HodesAugust 15, 2022

6min00
Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Atai completed a company-wide cost optimization initiative and an extensive pipeline review to both reduce its expected operating expenses and prioritize its capital resources on R&D programs. […]

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets